Chung Hyung-min

Chung Hyung-min

Chung Hyung-min
Born 1964 (age 5253)
South Korea
Residence South Korea
Nationality South Korean
Fields Stem cell research
Institutions CHA Stem Cell Institute, CHA University
Alma mater Konkuk University
Doctoral advisor Chung Kil-saeng
Known for Animal Biotechnology & Stem cell research
Notable awards 2004: Society for Assisted Reproductive Technology (SART) Prize Paper
2009: "CEO of Next generation" (for Bio Technology), Ministry of Knowledge Economy

Chung Hyung-min is a South Korean biotechnology professor.[1][2][3] He was appointed professor at CHA University in 1997 after obtaining his BA, MA and Ph.D degree at Konkuk University.

Currently, he is a professor of biomedical science at CHA University, Director of CHA Stemcell Institute, President of CHA Bio & Diostech Inc., Member of LMO Assessment Advisory Committee for Ministry of Health and Welfare, and Advisor for the Ministry of Knowledge Economy under the National Technical Advisory Committee. Dr Chung is a prominent leader in the field of stem cell research with over 20 years of experience.

His research aims at the development of stem cell therapies using human adult and embryonic stem cells. Primarily, his study focusses on the clinical applications of human embryonic stem cell-derived retinal cells, artificial blood and cardiovascular cells.

His research group became only the second in the world to be approved to conduct clinical application of human embryonic stem cells for the treatment of an orphan disease named Stargardt’s macular dystrophy.

Education

Awards

Publications

  1. Lee, MJ; Kim, J; Lee, KI; Shin, JM; Chae, JI; Chung, HM (2011). "Enhancement of wound healing by secretory factors of endothelial precursor cells derived from human embryonic stem cells". Cytotherapy. 13 (2): 165–78. PMID 21235296. doi:10.3109/14653249.2010.512632. 
  2. Kim, MJ; Park, JS; Kim, S; Moon, SH; Yang, HN; Park, KH; Chung, HM (2011). "Encapsulation of bone morphogenic protein-2 with Cbfa1-overexpressing osteogenic cells derived from human embryonic stem cells in hydrogel accelerates bone tissue regeneration". Stem cells and development. 20 (8): 1349–58. PMID 21126165. doi:10.1089/scd.2010.0311. 
  3. Kim, EY; Jeon, K; Park, HY; Han, YJ; Yang, BC; Park, SB; Chung, HM; Park, SP (2010). "Differences between cellular and molecular profiles of induced pluripotent stem cells generated from mouse embryonic fibroblasts". Cellular reprogramming. 12 (6): 627–39. PMC 2998986Freely accessible. PMID 20958217. doi:10.1089/cell.2010.0013. 
  4. Moon, SH; Kim, JS; Park, SJ; Lim, JJ; Lee, HJ; Lee, SM; Chung, HM (2011). "Effect of chromosome instability on the maintenance and differentiation of human embryonic stem cells in vitro and in vivo". Stem cell research. 6 (1): 50–9. PMID 20920899. doi:10.1016/j.scr.2010.08.006. 
  5. Park, SW; Jun Koh, Y; Jeon, J; Cho, YH; Jang, MJ; Kang, Y; Kim, MJ; Choi, C; et al. (2010). "Efficient differentiation of human pluripotent stem cells into functional CD34+ progenitor cells by combined modulation of the MEK/ERK and BMP4 signaling pathways". Blood. 116 (25): 5762–72. PMID 20884805. doi:10.1182/blood-2010-04-280719. 

References

  1. "Stem cells bring life to biotech industry". JoongAng Ilbo. 2012-01-25. Retrieved 2014-07-12.
  2. "Bioethics body approves first embryonic stem cell test". The Korea Herald. 2011-04-27. Retrieved 2014-07-12.
  3. "South Korea to Lift Ban On Human Stem Cell Research". US News and World Report. 2009-04-29. Retrieved 2014-07-12.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.